Tolterodine
Brand names: Detrusitol
Tolterodine is an antimuscarinic used for the symptoms of overactive bladder.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UK• 4 mg capsules taken orally once daily with water and swallowed whole. ( 2.1 ) • 2 mg capsules taken orally once daily with water and swallowed whole in the presence of: o mild to moderate hepatic impairment (Child-Pugh class A or B) ( 2.2 ) o severe renal impairment [Creatinine Clearance (CCr) 10-30 mL/min] ( 2.2 ) o drugs that are potent CYP3A4 inhibitors. ( 2.2 ) • Tolterodine tartrate extended-release capsules are not recommended for use in patients with CCr <10 mL/min. ( 2.2 ) • Tolterodine tartrate extended-release capsules are not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C). ( 2.2 ) 2.1 Dosing Information The recommended dose of tolterodine …
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2024-12-14. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Clinical monograph
How it works
It blocks muscarinic receptors in the bladder, reducing detrusor overactivity.
Prescribing in practice
- Antimuscarinic effects (dry mouth, constipation, blurred vision, and — in older people — confusion and falls) limit it; weigh the overall anticholinergic burden.
- Avoid in narrow-angle glaucoma, significant urinary retention and gastrointestinal obstruction.
- It can prolong the QT interval; reduce the dose in hepatic/renal impairment and with strong CYP inhibitors.
Monitoring
Review symptom benefit and anticholinergic effects, particularly cognition in older patients.
Counselling the patient
- Dry mouth and constipation are common.
- Report difficulty passing urine or new confusion.
Evidence & guidelines
An antimuscarinic option for overactive bladder (NICE NG123), mindful of anticholinergic burden in older people.
Reference: NICE NG123; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.